XTX Topco Ltd Trims Stock Position in BioAtla, Inc. (NASDAQ:BCAB)

XTX Topco Ltd trimmed its stake in BioAtla, Inc. (NASDAQ:BCAB) by 12.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 144,583 shares of the company’s stock after selling 19,784 shares during the period. XTX Topco Ltd owned approximately 0.30% of BioAtla worth $198,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. American Century Companies Inc. grew its holdings in shares of BioAtla by 36.1% during the second quarter. American Century Companies Inc. now owns 43,391 shares of the company’s stock worth $59,000 after purchasing an additional 11,503 shares during the last quarter. Price T Rowe Associates Inc. MD purchased a new position in BioAtla during the 1st quarter worth approximately $45,000. Massachusetts Financial Services Co. MA increased its position in BioAtla by 2.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 541,199 shares of the company’s stock worth $741,000 after buying an additional 14,737 shares during the period. Vanguard Group Inc. lifted its stake in BioAtla by 0.8% in the first quarter. Vanguard Group Inc. now owns 2,099,037 shares of the company’s stock valued at $7,221,000 after buying an additional 17,667 shares during the last quarter. Finally, Ground Swell Capital LLC acquired a new stake in shares of BioAtla in the second quarter valued at approximately $33,000. 77.23% of the stock is currently owned by institutional investors and hedge funds.

BioAtla Price Performance

BCAB opened at $1.63 on Monday. BioAtla, Inc. has a 52 week low of $1.14 and a 52 week high of $4.02. The business has a 50 day moving average price of $1.71 and a two-hundred day moving average price of $2.07. The company has a market cap of $78.43 million, a PE ratio of -0.65 and a beta of 1.06.

BioAtla (NASDAQ:BCAB) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.01. During the same period last year, the company earned ($0.75) EPS. As a group, sell-side analysts expect that BioAtla, Inc. will post -1.52 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, JMP Securities reaffirmed a “market outperform” rating and issued a $5.00 target price on shares of BioAtla in a report on Monday, September 16th.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.